The Rising Prevalence Of Cancer To Boost CAR T-Cell Therapy Market Growth

CAR T-Cell Therapy Market

CAR T-Cell Therapy Market (By Drug Type: Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others; By Indication: Lymphoma, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Others; By End User: Hospitals, Cancer Treatment Centers) - and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030

The global CAR T-Cell Therapy Market is estimated to be valued at US$ 2.19 billion in 2022 and is expected to exhibit a CAGR of 11.37 % over the forecast period, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

A person with a tumor that do not react to chemo such as melanoma or other therapeutics might be suggested to undergo Car T Cell Therapy. This therapy includes creating T cells with a gene alteration that will trigger the tumor cells, which proves to be fatal for a person. The Car T Cell Therapy procedure starts with a plasma extraction known as leukapheresis, in which physician extracts T cells from the body utilizing a special device.

Competitive Landscape:

Key players involved in the growth of global CAR T-Cell Therapy Market are Gilead Sciences, Inc. Kolon TissueGene, Inc., JW Therapeutics (Shanghai) Co., Ltd., Stempeutics Research PVT LTD, PHARMICELL Co., Ltd., Bristol-Myers Squibb Company, JCR Pharmaceuticals Co., Ltd., Novartis AG, MEDIPOST, Curocell, Inc. and ANTEROGEN. CO., LTD.

Market Key Drivers:

The rising prevalence of cancer is expected to augment the growth of the global CAR T-Cell Therapy for Market. For instance, as per ACS, around 18.1 million new cancer cases were reported in 2020 across the globe.

The robust product pipeline is projected to propel the growth of global CAR T-Cell Therapy Market. For instance, AUTO1, from Autolus Therapeutics plc, is experiencing a phase I trial to cure acute lymphoblastic leukemia in adults.

Covid-19 Impact Analysis:

The Covid-19 outbreak has adversely affected the growth of global CAR T-Cell Therapy for Market. The pandemic has considerably affected the management of adoptive cell therapy, especially CAR T-Cell therapy. The delay in the transference of human organs, imposition of strict lockdown, and confinement of residents and other things has interrupted the supply networks for these life-threatening drugs.

During the course of the forecast period, a rise in the number of products available on the market is anticipated to fuel the expansion of the worldwide Bovine Plasma Market.

Key Takeaways:

The global CAR T-Cell Therapy Market is anticipated to exhibit a CAGR of 11.37 % during the forecast period owing to the increasing incidences of non-Hodgkin lymphoma. For instance, as per WHO, around 544,352 new non-Hodgkin lymphoma cases were reported in 2022 across the globe.

Among regions, North America, Europe and Asia Pacific are expected to witness robust growth in global CAR T-Cell Therapy for Market due to rise in cancer diseases, rising cases of non-Hodgkin lymphoma, increasing product approvals and launches, rising healthcare infrastructure. For instance, as per ACS, around 1.9 million new cancer cases reported in U.S.